1. Home
  2. Labeler Index
  3. Takeda Pharmaceuticals America, Inc.
  4. 64764-123
  5. NDC Package Code: 64764-123-05 Oseni

NDC Package 64764-123-05 Oseni

Alogliptin And Pioglitazone Tablet, Film Coated Oral - View Billable Units, 11-Digit Format, RxNorm

Table of Contents

    1. Package Information
    2. Other Packages
    3. Frequently Asked Questions

Package Information

Find all the important details about this NDC Package code, including the 11-Digit NDC Billing number, billing units, wholesale price, RxNorm crosswalk, active ingredients, pharmacologic clasess, etc.

NDC Package Code:
64764-123-05
Package Description:
500 TABLET, FILM COATED in 1 BOTTLE
Product Code:
64764-123
Proprietary Name:
Oseni
Non-Proprietary Name:
Alogliptin And Pioglitazone
Substance Name:
Alogliptin Benzoate; Pioglitazone Hydrochloride
Usage Information:
This combination medication is used with a proper diet and exercise program to control high blood sugar in people with type 2 diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. Proper control of diabetes may also lessen your risk of a heart attack or stroke. This product contains 2 medications: alogliptin and pioglitazone. Alogliptin works by increasing levels of natural substances called incretins. Incretins help to control blood sugar by increasing insulin release, especially after a meal. They also decrease the amount of sugar your liver makes. Pioglitazone works by helping to restore your body's proper response to insulin.
11-Digit NDC Billing Format:
64764012305
NDC to RxNorm Crosswalk:
  • RxCUI: 1368410 - alogliptin 12.5 MG / pioglitazone 30 MG Oral Tablet
  • RxCUI: 1368410 - alogliptin 12.5 MG (as alogliptin benzoate 17 MG) / pioglitazone 30 MG (as pioglitazone hydrochloride 33.06 MG) Oral Tablet
  • RxCUI: 1368416 - Oseni 12.5 MG / 30 MG Oral Tablet
  • RxCUI: 1368416 - alogliptin 12.5 MG / pioglitazone 30 MG Oral Tablet [Oseni]
  • RxCUI: 1368416 - Oseni 12.5/30 (as alogliptin benzoate 17 MG / pioglitazone hydrochloride 33.06 MG) Oral Tablet
    • Product Type:
    Human Prescription Drug
    Labeler Name:
    Takeda Pharmaceuticals America, Inc.
    Dosage Form:
    Tablet, Film Coated - A solid dosage form that contains medicinal substances with or without suitable diluents and is coated with a thin layer of a water-insoluble or water-soluble polymer.
    Administration Route(s):
  • Oral - Administration to or by way of the mouth.
    • Active Ingredient(s):
  • ALOGLIPTIN BENZOATE 12.5 mg/1
  • PIOGLITAZONE HYDROCHLORIDE 30 mg/1
    • Pharmacologic Class(es):
  • Dipeptidyl Peptidase 4 Inhibitor - [EPC] (Established Pharmacologic Class)
  • Dipeptidyl Peptidase 4 Inhibitors - [MoA] (Mechanism of Action)
  • Peroxisome Proliferator Receptor alpha Agonist - [EPC] (Established Pharmacologic Class)
  • Peroxisome Proliferator Receptor gamma Agonist - [EPC] (Established Pharmacologic Class)
  • Peroxisome Proliferator-activated Receptor alpha Agonists - [MoA] (Mechanism of Action)
  • Peroxisome Proliferator-activated Receptor gamma Agonists - [MoA] (Mechanism of Action)
  • Thiazolidinedione - [EPC] (Established Pharmacologic Class)
  • Thiazolidinediones - [CS]
    • Sample Package:
    No
    FDA Application Number:
    NDA022426
    Marketing Category:
    NDA - A product marketed under an approved New Drug Application.
    Start Marketing Date:
    01-25-2013
    Listing Expiration Date:
    12-31-2024
    Exclude Flag:
    N
    Code Structure:

    The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

    * Please review the disclaimer below.

    Other Product Packages

    The following packages are also available for this product:

    NDC Package CodePackage Description
    64764-123-0330 TABLET, FILM COATED in 1 BOTTLE
    64764-123-0490 TABLET, FILM COATED in 1 BOTTLE

    * Please review the disclaimer below.

    Frequently Asked Questions

    What is NDC 64764-123-05?

    The NDC Packaged Code 64764-123-05 is assigned to a package of 500 tablet, film coated in 1 bottle of Oseni, a human prescription drug labeled by Takeda Pharmaceuticals America, Inc.. The product's dosage form is tablet, film coated and is administered via oral form.

    Is NDC 64764-123 included in the NDC Directory?

    Yes, Oseni with product code 64764-123 is active and included in the NDC Directory. The product was first marketed by Takeda Pharmaceuticals America, Inc. on January 25, 2013 and its listing in the NDC Directory is set to expire on December 31, 2024 if the product is not updated or renewed by the manufacturer.

    What is the 11-digit format for NDC 64764-123-05?

    The 11-digit format is 64764012305. The 11-digit billing format might be required by the Centers for Medicare & Medicaid Services (CMS) and other payers in billing claim forms.

    This package code is originally configured in a 5-3-2 segment 10-digit format and by adding a zero within the original NDC package code we can obtain the converted 11-digit format in a 5-4-2 segment configuration. The table below shows the 11-digit code conversion:

    10-Digit Format10-Digit Original Code11-Digit Format11-Digit Code
    5-3-264764-123-055-4-264764-0123-05